Key result
Colchicine reduced composite cardiovascular outcomes by approximately 60% (RR 0.44) in patients with established cardiovascular disease.
Why the study?
Does colchicine reduce composite cardiovascular outcomes and recurrent pericarditis or post-pericardiotomy syndrome in adult patients with cardiac diseases?
Meta-Analysis (n=3,431)
Does colchicine reduce composite cardiovascular outcomes and recurrent pericarditis or post-pericardiotomy syndrome in adult patients with cardiac diseases?
Effect estimate: RR 0.44 (95% CI 0.28-0.69)
p-value: p=0.0004
Colchicine significantly reduces composite cardiovascular outcomes in patients with established cardiovascular disease and reduces recurrent pericarditis, post-pericardiotomy syndrome, and peri-procedural atrial fibrillation, though it is associated with increased gastrointestinal side effects.
No takes yet. Share an insight, caveat, or question.
Supports adding colchicine to secondary prevention in established CVD; confirms efficacy in pooled randomized trials.
Verma et al. (2015) conducted a meta-analysis in Cardiac disease (n=3,431). Colchicine vs. Placebo or no therapy was evaluated on Composite cardiovascular outcome (RR 0.44, 95% CI 0.28-0.69, p=0.0004). Colchicine reduced composite cardiovascular outcomes by approximately 60% (RR 0.44) in patients with established cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: